Literature DB >> 22137543

Intravesical chondroitin sulfate inhibits recruitment of inflammatory cells in an acute acid damage "leaky bladder" model of cystitis.

Christopher D Engles1, Paul J Hauser, Shivon N Abdullah, Daniel J Culkin, Robert E Hurst.   

Abstract

OBJECTIVE: To investigate whether a physiologic effect of "glycosaminoglycan (GAG) replenishment therapy" altered recruitment of inflammatory cells in an acute bladder damage model. Replacement of the GAG layer with intravesically administered GAGs is an effective therapy for interstitial cystitis in at least some patients. Intravesically administered chondroitin sulfate was previously shown to bind to and restore the impermeability of surface-damaged ("leaky") urothelium to small ions.
METHODS: Rat bladders were damaged with 10 mM HCl. Negative control bladders were treated with phosphate-buffered saline. On the following day, the animal bladders were treated with 20 mg/mL chondroitin sulfate in phosphate-buffered saline, and the negative and positive controls were treated with phosphate-buffered saline alone. At 2 and 4 days after treatment with chondroitin sulfate, the rats were killed, and sections of their bladders were analyzed using toluidine blue staining for mast cell immunohistochemical labeling using antibodies against CD45 for lymphocytes and myeloperoxidase for neutrophils.
RESULTS: Chondroitin sulfate treatment reduced the recruitment, in a statistically significant manner, of inflammatory cells, including neutrophils and mast cells to the suburothelial space but did not alter recruitment of CD45-positive lymphocytes.
CONCLUSION: For the first time, we have demonstrated that intravesical GAG replenishment therapy also produces a physiologic effect of decreasing recruitment of inflammatory cells in an acute model of the damaged bladder. These findings support the use of intravesically administered GAG for bladder disorders that result from a loss of impermeability, including interstitial, radiation, and chemical cystitis, and possibly others as well.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137543      PMCID: PMC3274614          DOI: 10.1016/j.urology.2011.10.010

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  29 in total

1.  Abnormal expression of differentiation related proteins and proteoglycan core proteins in the urothelium of patients with interstitial cystitis.

Authors:  Paul J Hauser; Mikhail G Dozmorov; Barbara L Bane; Gennady Slobodov; Daniel J Culkin; Robert E Hurst
Journal:  J Urol       Date:  2007-12-20       Impact factor: 7.450

2.  Discovery of morphological subgroups that correlate with severity of symptoms in interstitial cystitis: a proposed biopsy classification system.

Authors:  Benjamin E Leiby; J Richard Landis; Kathleen J Propert; John E Tomaszewski
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

3.  Changes in urinary bladder smooth muscle function in response to colonic inflammation.

Authors:  R Noronha; H Akbarali; A Malykhina; R D Foreman; Beverley Greenwood-Van Meerveld
Journal:  Am J Physiol Renal Physiol       Date:  2007-08-22

4.  Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate.

Authors:  Paul J Hauser; David A Buethe; John Califano; Troy M Sofinowski; Daniel J Culkin; Robert E Hurst
Journal:  J Urol       Date:  2009-09-17       Impact factor: 7.450

Review 5.  What is new in bladder pain syndrome/interstitial cystitis?

Authors:  Philip Hanno; Jørgen Nordling; Arndt van Ophoven
Journal:  Curr Opin Urol       Date:  2008-07       Impact factor: 2.309

Review 6.  The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis.

Authors:  C Lowell Parsons
Journal:  Urology       Date:  2007-04       Impact factor: 2.649

Review 7.  Current diagnosis of interstitial cystitis: an evolving paradigm.

Authors:  Robert J Evans; Grannum R Sant
Journal:  Urology       Date:  2007-04       Impact factor: 2.649

8.  Urine is necessary to provoke bladder inflammation in protamine sulfate induced urothelial injury.

Authors:  Roberto Soler; Homero Bruschini; Marcos P Freire; Maria T Alves; Miguel Srougi; Valdemar Ortiz
Journal:  J Urol       Date:  2008-08-16       Impact factor: 7.450

9.  A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis.

Authors:  J Curtis Nickel; Blair Egerdie; Joe Downey; Rajiva Singh; Anthony Skehan; Leslie Carr; Karen Irvine-Bird
Journal:  BJU Int       Date:  2008-09-03       Impact factor: 5.588

Review 10.  Dysfunction of bladder urothelium and bladder urothelial cells in interstitial cystitis.

Authors:  Emmanuel Graham; Toby C Chai
Journal:  Curr Urol Rep       Date:  2006-11       Impact factor: 2.862

View more
  13 in total

1.  Basic research: GAGging the leaky bladder in IC.

Authors:  Mina Razzak
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

2.  Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis.

Authors:  Omer Gülpınar; Aytaç Kayış; Evren Süer; Mehmet İlker Gökçe; Adil Güçal Güçlü; Nihat Arıkan
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

3.  Contrast enhanced magnetic resonance imaging as a diagnostic tool to assess bladder permeability and associated colon cross talk: preclinical studies in a rat model.

Authors:  Rheal A Towner; Nataliya Smith; Debra Saunders; Samuel B Van Gordon; Amy B Wisniewski; Karl R Tyler; Beverley Greenwood-Van Meerveld; Robert E Hurst
Journal:  J Urol       Date:  2014-11-14       Impact factor: 7.450

4.  Standardized cranberry capsules for radiation cystitis in prostate cancer patients in New Zealand: a randomized double blinded, placebo controlled pilot study.

Authors:  Katelin Hamilton; Noelle C Bennett; Gordon Purdie; Patries M Herst
Journal:  Support Care Cancer       Date:  2014-07-04       Impact factor: 3.603

Review 5.  Intravesical treatments of bladder pain syndrome/interstitial cystitis.

Authors:  Jochen Neuhaus; Thilo Schwalenberg
Journal:  Nat Rev Urol       Date:  2012-11-27       Impact factor: 14.432

6.  Intravesical Glycosaminoglycan Replacement with Chondroitin Sulphate (Gepan(®) instill) in Patients with Chronic Radiotherapy- or Chemotherapy-Associated Cystitis.

Authors:  Thilo Schwalenberg; Frank Peter Berger; Lars Christian Horn; Phuc Ho Thi; Jens-Uwe Stolzenburg; Jochen Neuhaus
Journal:  Clin Drug Investig       Date:  2015-08       Impact factor: 2.859

Review 7.  Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction.

Authors:  Mohammad Sajjad Rahnama'i; Gommert A Van Koeveringe; Philip E Van Kerrebroeck
Journal:  Nephrourol Mon       Date:  2013-09-10

8.  Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan.

Authors:  Won Yong Lee; Justin R Savage; Jianxing Zhang; Wanjian Jia; Siam Oottamasathien; Glenn D Prestwich
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

9.  Increased bladder permeability in interstitial cystitis/painful bladder syndrome.

Authors:  Robert E Hurst; Beverley Greenwood-Van Meerveld; Amy B Wisniewski; Samuel VanGordon; HsuehKung Lin; Bradley P Kropp; Rheal A Towner
Journal:  Transl Androl Urol       Date:  2015-10

10.  Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis.

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.